Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Trimmed by Impax Asset Management Group plc

Impax Asset Management Group plc trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,270 shares of the life sciences company's stock after selling 7,383 shares during the quarter. Impax Asset Management Group plc's holdings in Illumina were worth $3,988,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. Rakuten Securities Inc. increased its stake in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. purchased a new position in Illumina in the 1st quarter valued at approximately $33,000. Fourth Dimension Wealth LLC purchased a new position in Illumina in the 4th quarter valued at approximately $40,000. PFS Partners LLC increased its stake in Illumina by 400.0% in the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC increased its stake in Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Stephens reaffirmed an "overweight" rating and issued a $105.00 price objective on shares of Illumina in a research note on Tuesday, May 20th. Canaccord Genuity Group raised their price target on Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research report on Wednesday, June 11th. Evercore ISI raised their price target on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research report on Tuesday. Guggenheim dropped their price target on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Barclays reissued an "underweight" rating and set a $85.00 price target (up previously from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $127.16.

Illumina Trading Down 2.1%

Illumina stock traded down $2.05 during midday trading on Wednesday, reaching $97.22. The stock had a trading volume of 2,176,168 shares, compared to its average volume of 2,153,291. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The stock has a market capitalization of $15.39 billion, a PE ratio of -16.02, a price-to-earnings-growth ratio of 1.91 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The stock's 50-day simple moving average is $85.88 and its 200 day simple moving average is $96.96.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.98 earnings per share. Analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.